Pd13-02 Treatment Trends of a Large Active Surveillance Cohort for Men With Prostate Cancer

You have accessJournal of UrologyProstate Cancer: Localized: Active Surveillance I (PD13)1 May 2024PD13-02 TREATMENT TRENDS OF A LARGE ACTIVE SURVEILLANCE COHORT FOR MEN WITH PROSTATE CANCER Brian Dinerman, Daniel Baetzhold, K. Kent Chevli, and John Rutkowski Brian DinermanBrian Dinerman , Daniel BaetzholdDaniel Baetzhold , K. Kent ChevliK. Kent Chevli , and John RutkowskiJohn Rutkowski View All Author Informationhttps://doi.org/10.1097/01.JU.0001009552.62973.71.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Active surveillance (AS) is widely accepted as a treatment pathway for low-risk and favorable intermediate-risk localized prostate cancer. We aimed to report the long-term progression of patients on AS to treatment. METHODS: In a retrospective cohort study performed at a single institution center, 2521 men with low or favorable intermediate risk prostate cancer were managed with an active surveillance protocol from 2000-2023. Main outcomes measured were overall survival and time to treatment. RESULTS: Of the patient enrolled, 620 (24.6%) entered treatment, 395 (15.7%) patients died, 34 (1.3%) had metastasis, and 6 (17.6% of those with metastasis) died with metastasis. By race, 2337 were (92.7%) white, 143 (5.7%) African-American, 20 (0.8%) American Indian/Alaskan, 14 (0.6%) Asian, and 7 (0.2%) other. Median follow-up was 4 years and maximum follow-up time was 22.2 years. Median age of patients was 73.8 with a range of 43.8 to 98.1 years. At 5, 10, and 15 years, 71.3%, 62.7%, and 52% of patients remained untreated and on AS. For patients with Gleason score (GS) 3+3=6 on AS at 5 and 10 years, 81.4% and 76.3% remained untreated. Similarly, patients with GS 3+4=7 demonstrated 41.5% and 27.4% untreated rates. CONCLUSIONS: To our knowledge, we report the largest AS cohort examining time to treatment. AS for favorable-risk prostate cancer seems safe and effective in the 10-year timespan. In our study, 24.6% of patients progressed to treatment and 1.3% of patient developed metastasis. Additionally, 0.2% of patients on AS died with metastasis. Download PPTDownload PPTDownload PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e262 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Brian Dinerman More articles by this author Daniel Baetzhold More articles by this author K. Kent Chevli More articles by this author John Rutkowski More articles by this author Expand All Advertisement PDF downloadLoading ...